Bauml JM, et al. - From within the Veterans Health Affairs system, 4,520 candidates were studied to compare the outcomes of head and neck squamous cell carcinoma (HNSCC) treated with radiation therapy (RT) plus cisplatin vs RT plus cetuximab. The candidates were younger and with fewer comorbidities in the cisplatin group. An association of cetuximab treatment with significantly inferior overall survival was observed after matching propensity score. Hence, they favored the use of cisplatin plus RT in the nonoperative management of stage III to IVb HNSCC.